Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.
KARD · Kardigan, Inc. · Documents
The latest filing states the doubt was alleviated.
“the Company previously concluded that recurring losses, negative cash flows from operations, and limited liquidity raised substantial doubt about its ability to continue as a going concern. In June 2026, the Company completed its IPO and received net proceeds of approximately $422.5 million. Upon closing of the IPO and receipt of the associated net proceeds, the Company alleviated the substantial doubt that previously existed.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Cardigan said six-month data for Danicamptiv in genetic cardiomyopathy comes in the second quarter, with peak VO2 correlations. Week 48 data for Atasaguat in Catalyst AV will confirm AVA and peak VO2, with registrational trial details in the first half of next year. About 80% of mild and moderate aortic stenosis patients show cardiac damage.
Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.
Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.
Kardigan completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis, moving primary endpoint assessment to Week 48 and topline data to 2H 2027.
Kardigan appointed Kristin Reinke as a Class I director and Audit Committee chair effective September 29, 2026, after Doug Giordano resigned from the board and committee; Reinke will receive stock options valued at $650,000 and cash compensation.